Loading clinical trials...
Loading clinical trials...
A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies
Conditions
Interventions
LBH589
Locations
7
United States
Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia
Augusta, Georgia, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
MD Anderson Cancer Center/University of Texas
Houston, Texas, United States
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Prahran, Victoria, Australia
Novartis Investigative Site
Frankfurt/M, Germany
Start Date
March 1, 2003
Primary Completion Date
December 3, 2009
Completion Date
December 3, 2009
Last Updated
January 5, 2021
NCT07249528
NCT04570423
NCT06735690
NCT05564390
NCT00131014
NCT06074666
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions